
OSE Immunotherapeutics SA
PAR:OSE

OSE Immunotherapeutics SA
Current Portion of Long-Term Debt
OSE Immunotherapeutics SA
Current Portion of Long-Term Debt Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
Company | Current Portion of Long-Term Debt | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
---|---|---|---|---|---|---|
![]() |
OSE Immunotherapeutics SA
PAR:OSE
|
Current Portion of Long-Term Debt
€3.9m
|
CAGR 3-Years
75%
|
CAGR 5-Years
33%
|
CAGR 10-Years
N/A
|
|
![]() |
Valneva SE
PAR:VLA
|
Current Portion of Long-Term Debt
€23.4m
|
CAGR 3-Years
32%
|
CAGR 5-Years
40%
|
CAGR 10-Years
13%
|
|
![]() |
Nanobiotix SA
PAR:NANO
|
Current Portion of Long-Term Debt
€4.2m
|
CAGR 3-Years
-12%
|
CAGR 5-Years
20%
|
CAGR 10-Years
N/A
|
|
G
|
Genfit SA
PAR:GNFT
|
Current Portion of Long-Term Debt
€8m
|
CAGR 3-Years
41%
|
CAGR 5-Years
13%
|
CAGR 10-Years
45%
|
|
![]() |
Inventiva SA
PAR:IVA
|
Current Portion of Long-Term Debt
€5.7m
|
CAGR 3-Years
64%
|
CAGR 5-Years
124%
|
CAGR 10-Years
N/A
|
|
![]() |
Eurobio Scientific SA
PAR:ALERS
|
Current Portion of Long-Term Debt
€15.3m
|
CAGR 3-Years
53%
|
CAGR 5-Years
14%
|
CAGR 10-Years
36%
|
OSE Immunotherapeutics SA
Glance View
OSE Immunotherapeutics SA develops immunotherapy products for cancer and auto-immune disease. The company is headquartered in Nantes, Pays De La Loire and currently employs 61 full-time employees. The company went IPO on 2015-03-30. The company develops immunotherapies, directly or through partnerships, for the activation and regulation of the immune system in immuno-oncology and in autoimmune diseases. The firm's research and development in immunology is based on 3 platforms, such as T cell-based vaccines, Immuno-Oncology (myeloid targets) and Auto-Immunity & Inflammation. The company provides technological and scientific platforms: neoepitopes, agonist or antagonist monoclonal antibodies, ideally positioned to fight cancer and autoimmune diseases.

See Also
What is OSE Immunotherapeutics SA's Current Portion of Long-Term Debt?
Current Portion of Long-Term Debt
3.9m
EUR
Based on the financial report for Jun 30, 2024, OSE Immunotherapeutics SA's Current Portion of Long-Term Debt amounts to 3.9m EUR.
What is OSE Immunotherapeutics SA's Current Portion of Long-Term Debt growth rate?
Current Portion of Long-Term Debt CAGR 5Y
33%
Over the last year, the Current Portion of Long-Term Debt growth was -38%. The average annual Current Portion of Long-Term Debt growth rates for OSE Immunotherapeutics SA have been 75% over the past three years , 33% over the past five years .